General Announcement::Company Statement

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
01-Dec-2024 20:38:15
Status
New
Announcement Sub Title
Company Statement
Announcement Reference
SG241201OTHRZFU9
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
02/12/2024 00:01:00
Description (Please provide a detailed description of the event in the box below)
Company Statement - U.S.FDA Approves Biocon Biologics YESINTEK Bmab 1200 biosimilar to J&J's Stelara (Ustekinumab)

Attachments

BBL_SGX_USFDA_01122024.pdf
Total size =364K